Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Imaging nigral pathology and clinical progression in Parkinson's disease.

Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M, Yang QX, Huang X.

Mov Disord. 2012 Nov;27(13):1636-43. doi: 10.1002/mds.25182. Epub 2012 Sep 24.

2.

Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease.

Aquino D, Contarino V, Albanese A, Minati L, Farina L, Grisoli M, Romita L, Elia AE, Bruzzone MG, Chiapparini L.

Neurol Sci. 2014 May;35(5):753-8. doi: 10.1007/s10072-013-1595-2. Epub 2013 Dec 11. Erratum in: Neurol Sci. 2014 May;35(5):759. Elia, Antonio [corrected to Elia, Antonio Emanuele]; Romito, Luigi [added].

PMID:
24337946
3.

Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease.

Prakash BD, Sitoh YY, Tan LC, Au WL.

Parkinsonism Relat Disord. 2012 Nov;18(9):1029-33. doi: 10.1016/j.parkreldis.2012.05.021. Epub 2012 Jun 16.

PMID:
22705126
4.

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM.

Neurology. 2009 Apr 21;72(16):1378-84. doi: 10.1212/01.wnl.0000340982.01727.6e. Epub 2009 Jan 7. Erratum in: Neurology. 2009 Jun 9;72(23):2059.

5.

Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.

Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X.

Mov Disord. 2011 Aug 1;26(9):1627-32. doi: 10.1002/mds.23643. Epub 2011 May 26.

6.

Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.

Scherfler C, Esterhammer R, Nocker M, Mahlknecht P, Stockner H, Warwitz B, Spielberger S, Pinter B, Donnemiller E, Decristoforo C, Virgolini I, Schocke M, Poewe W, Seppi K.

Brain. 2013 Oct;136(Pt 10):3028-37. doi: 10.1093/brain/awt234. Epub 2013 Sep 6.

PMID:
24014521
7.

Microstructural changes in the substantia nigra of asymptomatic agricultural workers.

Du G, Lewis MM, Sterling NW, Kong L, Chen H, Mailman RB, Huang X.

Neurotoxicol Teratol. 2014 Jan-Feb;41:60-4. doi: 10.1016/j.ntt.2013.12.001. Epub 2013 Dec 12.

8.

MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra.

Skorpil M, Söderlund V, Sundin A, Svenningsson P.

J Parkinsons Dis. 2012;2(2):171-80. doi: 10.3233/JPD-2012-12091.

PMID:
23939442
9.

Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD).

Esterhammer R, Seppi K, Reiter E, Pinter B, Mueller C, Kremser C, Zitzelsberger T, Nocker M, Scherfler C, Poewe W, Schocke M.

PLoS One. 2015 Dec 29;10(12):e0145493. doi: 10.1371/journal.pone.0145493. eCollection 2015.

10.

Fractional anisotropy in the substantia nigra in Parkinson's disease: a complex picture.

Lenfeldt N, Larsson A, Nyberg L, Birgander R, Forsgren L.

Eur J Neurol. 2015 Oct;22(10):1408-14. doi: 10.1111/ene.12760. Epub 2015 Jun 29.

PMID:
26118635
11.

Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis.

Schwarz ST, Abaei M, Gontu V, Morgan PS, Bajaj N, Auer DP.

Neuroimage Clin. 2013 Oct 14;3:481-8. doi: 10.1016/j.nicl.2013.10.006. eCollection 2013.

12.

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.

Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Ranola M, Marek K.

Mov Disord. 2015 Dec;30(14):1885-92. doi: 10.1002/mds.26325. Epub 2015 Aug 11.

PMID:
26260437
13.

Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U.

Brain. 2010 Nov;133(11):3423-33. doi: 10.1093/brain/awq212. Epub 2010 Aug 23.

PMID:
20736190
14.

Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.

Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA.

Neurology. 1995 Jun;45(6):1138-43. Erratum in: Neurology 1995 Jul;45(7):1420.

PMID:
7783878
15.

Quantitative Susceptibility Mapping in Parkinson's Disease.

Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, Homayoon N, Katschnig-Winter P, Koegl-Wallner M, Pendl T, Stoegerer EM, Wenzel K, Fazekas F, Ropele S, Reichenbach JR, Schmidt R, Schwingenschuh P.

PLoS One. 2016 Sep 6;11(9):e0162460. doi: 10.1371/journal.pone.0162460. eCollection 2016.

16.

Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study.

Zhang Y, Wu IW, Tosun D, Foster E, Schuff N; Parkinson’s Progression Markers Initiative.

PLoS One. 2016 Oct 31;11(10):e0165540. doi: 10.1371/journal.pone.0165540. eCollection 2016.

17.

Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F.

PLoS One. 2013;8(3):e57904. doi: 10.1371/journal.pone.0057904. Epub 2013 Mar 1.

18.

Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, Mailman RB, Huang X.

Mov Disord. 2016 Mar;31(3):317-24. doi: 10.1002/mds.26417. Epub 2015 Sep 12.

19.

Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.

Reimão S, Ferreira S, Nunes RG, Pita Lobo P, Neutel D, Abreu D, Gonçalves N, Campos J, Ferreira JJ.

Eur J Neurol. 2016 Feb;23(2):368-74. doi: 10.1111/ene.12838. Epub 2015 Oct 31.

PMID:
26518135
20.

Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.

Langley J, Huddleston DE, Merritt M, Chen X, McMurray R, Silver M, Factor SA, Hu X.

Hum Brain Mapp. 2016 Jul;37(7):2547-56. doi: 10.1002/hbm.23192. Epub 2016 Mar 29.

Supplemental Content

Support Center